Table 2 Treatment profile
Variable | Total (n = 38) |
|---|---|
TACE method, n (%) | |
cTACE | 20 (52.6%) |
D-TACE | 17 (44.7%) |
Unknown | 1 (2.6%) |
TACE sessions, n (range) | 3 (1, 13) |
Regorafenib initial dosage, n (%) | |
20Â mg/d | 1 (2.6%) |
80Â mg/d | 10 (26.3%) |
120Â mg/d | 15 (39.5%) |
160Â mg/d | 11 (28.9%) |
Unknown | 1 (2.6%) |
Stopped regorafenib | 15 (39.5%) |
Reasons for stopping | |
Progression | 9 (23.7%) |
Intolerance | 5 (13.2%) |
Other | 1 (2.6%) |